Development of a 3D Imaging Diagnostic Tool for the Improved Characterization of Metastatic Melanoma

开发 3D 成像诊断工具以改善转移性黑色素瘤的表征

• 批准号: 10400201
• 负责人: Thomas Steven Villani
• 金额: $ 78.53万
• 依托单位: VISIKOL, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-01 至 2023-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10400201
• 关键词: 3-Dimensional; Address; Adjuvant; Adjuvant Therapy; American Joint Committee on Cancer; Archives; Axillary lymph node group; Biological Assay; Biopsy Specimen; Caring; Cessation of life; Classification; Clinical; Clinical Laboratory Improvement Amendments; Clinical Research; Clinical Treatment; Computer software; Detection; Development; Diagnosis; Disease; Distant; Documentation; Economics; Evaluation; Excision; Guidelines; Histologic; Histopathology; Human Resources; Image; In Situ; Incidence; Label; Laboratories; Malignant Neoplasms; Metastatic Melanoma; Monitor; National Comprehensive Cancer Network; Neoplasm Metastasis; Nivolumab; Nonmetastatic; Operative Surgical Procedures; Outcome; Pathologist; Pathology; Patient-Focused Outcomes; Patients; Phase; Pilot Projects; Population; Primary Neoplasm; Probability; Procedures; Process; Proliferating; Protocols documentation; Quality-Adjusted Life Years; Recurrence; Reporting; Reproducibility; Sampling; Sensitivity and Specificity; Sentinel Lymph Node; Sentinel Lymph Node Biopsy; Skin Cancer; Specificity; Specimen; Statistical Models; Surveys; Testing; Three-Dimensional Imaging; Tissue imaging; Tissues; Translating; Treatment Protocols; Validation; Work; assay development; base; cancer cell; chemotherapy; clinical effect; density; diagnostic assay; diagnostic platform; diagnostic strategy; diagnostic tool; digital; digital pathology; economic value; experience; follow-up; imager; imaging approach; improved; improved outcome; interest; lymph nodes; malignant breast neoplasm; melanocyte; melanoma; neoplastic cell; software development; tissue processing; tool

Summary The objective of this Phase II project is to improve outcomes and survival for patients with melanoma by reducing the number of false negative sentinel lymph node biopsies wherein metastatic disease is missed through conventional tissue processing and histological characterization. It is estimated that 4,200 patients are misdiagnosed in this manner in the US per year which results in more conservative treatment regimens for these patients than is required to effectively treat their disease. The outcome of patients not receiving the proper treatment regimen is that they experience a three-year reduction in ten-year survival which on a quality adjusted life year basis translates into a $1.2 billion economic loss. To address this problem, we have developed a three-dimensional tissue imaging and digital analysis approach which allows for the complete characterization of sentinel lymph node biopsy tissues and the identification of isolated tumor cells and micro- metastases that are commonly missed with traditional histopathology. We have demonstrated through our preliminary studies that using this approach we can identify these cancer cells in tissues that were previously characterized as node negative and that we can differentiate true negative from false negative samples. The focus of this project is to take this approach and transform it into a CLIA diagnostic assay that can be offered as a laboratory developed test to patients with negative sentinel lymph node biopsies at the conclusion of this Phase II work. Initially, the test will be offered following traditional tissue evaluation but eventually could be used as a primary diagnostic approach for all melanoma sentinel lymph node biopsy tissues. The development of this assay will be completed through conducting a retrospective clinical study in partnership with Cedars-Sinai with archived negative sentinel lymph node biopsy tissue blocks where the approach will be used to characterize these samples in their entirety. Through this study, we will demonstrate the accuracy, specificity and sensitivity of the test and will be able to quantify the extent to which it reduces the incidence of false negatives in the characterization of sentinel lymph node biopsies. Through the execution of this clinical study, we will build a statistical model that will threshold samples based upon their underlying three- dimensional features (e.g. total number of cancer cells, cancer cell aggregate volume, density of cancer cells) and classify them as ‘no metastases present’ (i.e. true negative) or ‘metastases present’ (i.e. true positive). Furthermore, the software we develop will for positive samples describe where a section should be taken from the sample for confirmation by a Visikol pathologist using traditional histopathology such that the report from the assay fits into the traditional classification paradigm. Lastly, we will transform our digital pathology software analysis approach into a 21 CFR part 11 compliant application which will be required at the conclusion of the project to start offering the assay as a CLIA test. To support this approach and to allow for the launch of a laboratory developed test, we will also build the validation documentation package and associated tests required to demonstrate the range, specificity, reproducibility, accuracy and precision of the assay. Therefore, at the conclusion of this project we will have built and validated an assay which can start to be offered to patients following the build-out of a CLIA lab and staffing with clinical personnel.

总结